Juno Therapeutics to Highlight Advancing Immuno-oncology Portfolio at the 2016 American Society of Clinical Oncology Annual Meeting

- New efficacy, safety, and durability data for JCAR014 in ALL, NHL, and CLL -

- First clinical results for JCAR017 with fludarabine/cyclophosphamide pre-conditioning regimen in pediatric ALL -

SEATTLE--()--Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced that in partnership with its collaborators it will present key clinical updates on its investigational products JCAR014, JCAR015 and JCAR017 at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2016 in Chicago, Illinois from June 3-7.

JCAR014, JCAR015 and JCAR017 are chimeric antigen receptor (CAR) T cell product candidates that target CD19, a protein expressed on the surface of almost all B cell malignancies, including acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and chronic lymphocytic leukemia (CLL). New data from the ongoing JCAR014 trial in patients with relapsed or refractory ALL, NHL, or CLL will be presented, with increased patient numbers and longer duration of follow-up compared to previous presentations. Investigators will also present updated data from the ongoing trial of JCAR017 in children with relapsed or refractory ALL, including the first experience of patients treated with the pre-conditioning regimen of fludarabine/cyclophosphamide. Ongoing data from the phase I experience of JCAR015 will also be presented, including in adult patients with relapsed or refractory ALL.

Key data presentations at ASCO include:

JCAR014

  • Rate of Durable Complete Response in ALL, NHL, and CLL After Immunotherapy with Optimized Lymphodepletion and Defined Composition CD19 CAR-T Cells
    • Oral abstract 102
    • Presenter: Cameron J. Turtle, MBBS, Ph.D. of the Fred Hutchinson Cancer Research Center
    • Date: Saturday, June 4, 2016: 8:48 a.m. Central Time
    • Location: Hall D1

JCAR017

  • Prolonged Functional Persistence of CD19 CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Determines Durability of MRD-Negative ALL Remission
    • Presenter: Rebecca Gardner, M.D. of Seattle Children’s Research Institute
    • Date: Sunday, June 5, 2016: 8:00 – 11:30 a.m. Central Time
    • Location: Hall A, Poster Board #370

JCAR015

  • Impact of Disease Burden on Long-Term Outcome of 19-28z CAR Modified T Cells in Adult Patients with Relapsed B-ALL
    • Presenter: Jae H. Park, M.D. of Memorial Sloan Kettering Cancer Center
    • Date: Saturday, June 4, 2016: 4:00 p.m. Central Time
    • Location: Arie Crown Theatre
  • Updated Results: Phase I Trial of Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL Following Initial Purine Analog-Based Therapy
    • Presenter: Mark B. Geyer, M.D., Department of Medicine, Memorial Sloan Kettering Cancer Center
    • Date: Monday, June 6, 2016: 8:00 – 11:30 a.m. Central Time
    • Location: Hall A, Poster Board #82

About Juno’s Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) Technologies

Juno’s CAR and TCR technologies genetically engineer T cells to recognize and kill cancer cells. Juno’s CAR T cell technology inserts a gene for a particular CAR into the T cell, enabling it to recognize cancer cells based on the expression of a specific protein located on the cell surface. Juno’s TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell. When either type of engineered T cell engages the target protein on the cancer cell, it initiates a cell-killing response against the cancer cell. JCAR014, JCAR015, and JCAR017 are investigational product candidates and their safety and efficacy have not been established.

About Juno

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno’s long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world’s leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children’s Research Institute, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19 directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children’s Research Hospital.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including statements regarding Juno’s mission, progress, clinical benefits, clinical trial results and the implications thereof, planned presentations at ASCO, clinical trial plans, and emerging medical trends. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno’s product development activities and clinical trials; Juno’s ability to obtain regulatory approval for and to commercialize its product candidates; Juno’s ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno’s competitors with respect to competing treatments and technologies; Juno’s dependence on third-party collaborators and other contractors in Juno’s research and development activities, including for the conduct of clinical trials and the manufacture of Juno’s product candidates; Juno’s dependence on Celgene for the development and commercialization outside of North America and China of Juno’s CD19 product candidates and any other product candidates for which Celgene exercises an option; Juno’s dependence on JW Biotechnology (Shanghai) Co., Ltd, over which Juno does not exercise complete control, for the development and commercialization of product candidates in China; Juno’s ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno’s business in general, see Juno’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2016 and Juno’s other periodic reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Juno disclaims any obligation to update these forward-looking statements.

Contacts

Juno Therapeutics, Inc.
Investor Relations:
Nicole Keith, 206-566-5521
nikki.keith@junotherapeutics.com
or
Media:
Christopher Williams, 206-566-5660
chris.williams@junotherapeutics.com

Contacts

Juno Therapeutics, Inc.
Investor Relations:
Nicole Keith, 206-566-5521
nikki.keith@junotherapeutics.com
or
Media:
Christopher Williams, 206-566-5660
chris.williams@junotherapeutics.com